Skip to main content
. 2026 Oct 9;18(10):1281. doi: 10.3390/pharmaceutics18101281
AMPK AMP-activated protein kinase
Aib α-aminoisobutyric acid
ActRII activin type II receptor
AMYR amylin receptor
CB1R cannabinoid type 1 receptor
cAMP cyclic adenosine monophosphate
CTR calcitonin receptor
EC50 half-maximal effective concentration
Fc fragment crystallizable region (of an antibody)
GABA gamma-aminobutyric acid
GPCR G protein-coupled receptor
ERK extracellular signal-regulated kinase
Gi/o inhibitory G protein alpha subunits (Gi and Go)
Gs stimulatory G protein alpha subunit
K_D (Kd) equilibrium dissociation constant
Ki inhibition constant
GLP-1R Glucagon-like peptide-1 receptor
GIPR Glucose-dependent insulinotropic polypeptide receptor
GCGR Glucagon receptor
GDF15 Growth differentiation factor 15
IC50 half-maximal inhibitory concentration
LEPR Leptin receptor
MC1R melanocortin-1 receptor
MC4R Melanocortin-4 receptor
MAOI monoamine oxidase inhibitor
MEN 2 multiple endocrine neoplasia syndrome type 2
MTC Medullary thyroid carcinoma
NFAT nuclear factor of activated T cells
NE Norepinephrine
NTS nucleus tractus solitarius
nM nanomolar
pM picomolar
µM micromolar
POMC pro-opiomelanocortin
RAMP Receptor activity-modifying protein
SGLT2 sodium–glucose cotransporter 2
GFRAL GDNF family receptor alpha-like
RET RET receptor tyrosine kinase